SEARCH WITHIN CONTENT
VOLUME 7 , ISSUE 1 ( Jan-Jun, 2018 ) > List of Articles
Syed Ahmed Hussain
Citation Information : Hussain SA. PG - 42: Expression of Her2/Neu in Breast Carcinoma at A Tertiary Care Centre. 2018; 7 (1):54-54.
License: CC BY-NC 4.0
Published Online: 01-06-2018
Copyright Statement: Copyright © 2018; The Author(s).
Introduction: Breast carcinoma is associated with high mortality and morbidity. The overall patient survival is determined by prognostic factors. HER2/neu status is an important immunohistochemical evaluation and is related to high grade tumor and poorer prognosis but favourable response to monoclonal antibody therapy and disease survival. Hence the present study investigates correlation between presence of HER2/neu and various clinicopathological parameters in primary breast carcinomas at our institution. Methods: Clinical data was obtained from hospital records. The gross details were noted upon arrival of specimens in our department. The sections of carcinoma breast cases were subjected to immunohistohemistry study of HER2/neu. HER2/neu status was correlated with various clinicopathological parameters. Results: There was a significant statistical association between HER2/neu expression with clinical stage (p= 0.029), histological grade (p= 0.038) as well as lymph node involvement (p= 0.022). Expression of HER2/neu expression was increased in tumour size of more than 2 cms (72.46%), higher tumour grade (87.03%) and lymph node metastases (89.47%). The major histological subtype was Infiltrating duct carcinoma and 35.18% of them showed HER2/neu expression. All the other histological subtypes were negative for HER2/neu. Meanwhile there was no significant association of HER2/neu expression with age, clinical stage, tumour size. Conclusion: The study indicates that HER2/neu is a powerful predictor of poor prognosis due to its association with prognostic parameters like tumor size, high mitotic grade, tumor grade, lymph node enlargement and clinical stage.
© Jaypee Brothers Medical Publishers (P) LTD.